Medicare Coverage Expansion Changed Benzodiazepine Utilization More Clearly Than Cost

A historical coverage study found an immediate utilization increase after Medicare Part D began covering benzodiazepines.

What the source reports

Using survey and claims information spanning 2006–2017, the investigators compared trends before and after the 2013 expansion. Benzodiazepine utilization showed an immediate increase followed by a declining trend. The analysis did not find significant corresponding level or trend changes in average cost.

Limits of the evidence

This quasi-experimental study concerns a historical policy change. Some non-Part-D prescriptions were self-reported and may have been missed. Utilization does not establish adherence, clinical benefit, inappropriate prescribing, or impairment, and other changing influences may remain.

Implications for forensic review

The paper is useful when interpreting prescription trends: a change in payment access can alter measured use without proving a change in disease or misuse. It should not be cited as a current insurance-coverage guide or as evidence that an individual beneficiary took a prescribed dose.

Source and related reading

Source reviewed: Impact of Medicare prescription drug Part D coverage expansion on utilisation and financial burden o (PMC8679099). This article summarizes the supplied paper; forensic applications above are interpretive analysis.

Related reading: A Pediatric Liberation Bundle Changed More Than Benzodiazepine Exposure; Takotsubo During Benzodiazepine Withdrawal Requires More Than a Medication Gap.